The European Medicines Agency adopted a negative opinion on Zevra Therapeutics' MAA, while Pomerantz LLP simultaneously investigated securities fraud claims.
1 report, 1 independent
Updated Aug 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The European Medicines Agency adopted a negative opinion on Zevra Therapeutics' MAA, while Pomerantz LLP simultaneously investigated securities fraud claims.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
European Medicines Agency
highest regulatory authority on medicines in the European Union